Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¹æ»ç¼±ÀÇ Ç×¾ÏÀÛ¿ë¿¡ ´ëÇÑ ÀçÁ¶ÇÕ TNF-¥áÀÇ È¿°ú Potentiation of Antitumor Effect of Radiotherapy by Recombinant Tumor Necrosis Factor-¥á

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 1998³â 16±Ç 3È£ p.225 ~ 231
¼ºÁø½Ç, ±è±Í¾ð, ¼­Ã¢¿Á, ½ÅÇ×ö,
¼Ò¼Ó »ó¼¼Á¤º¸
¼ºÁø½Ç (  ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ Ä¡·á¹æ»ç¼±°úÇб³½Ç

±è±Í¾ð (  ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ Ä¡·á¹æ»ç¼±°úÇб³½Ç
¼­Ã¢¿Á (  ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ Ä¡·á¹æ»ç¼±°úÇб³½Ç
½ÅÇ×ö (  ) 
ÇÑÈ¿°úÇбâ¼ú¿¬±¸¼Ò

Abstract

¸ñ Àû : ¸¶¿ì½º µ¿Á¾¾Ï¿¡ TNF-¥á¿Í ¹æ»ç¼±À» º´¿ëÇÏ¿© ¹æ»ç¼±ÀÇ Ç×¾Ï È¿°ú°¡ TNF-¥á¿¡
ÀÇÇÏ¿© Áõ°­µÉ ¼ö ÀÖ´ÂÁö ¿¬±¸ÇÏ°íÀÚ ÇÏ¿´´Ù.
´ë»ó ¹× ¹æ¹ý : C3Hf/HeJ ¸¶¿ì½º¿¡ À¯¹æ¾ÏÀÎ MCa-K, MCa-4, ³­¼Ò¾ÏÀÎ OCa-I, ±×¸®°í
°£¾ÏÀÎ HCa-I µî Á¾¾çÀ» À̽ÄÇÏ¿´´Ù. Á¾¾çÀÇ Å©±â°¡ 6 mm¿¡ À̸¦ ¶§ TNF-¥á, ¹æ»ç¼±, ¶Ç
´Â º´¿ë±º µî ½ÇÇ豺À» ³ª´©¾î ÀûÀýÇÑ Ä¡·á¸¦ ÇÏ¿´´Ù. ¹æ»ç¼±Á¶»ç´Â Cobalt-60 ¹æ»ç¼± Á¶»ç
±â¸¦ ÀÌ¿ëÇÏ¿© HCa-I ¿¡´Â 30 Gy¸¦, ³ª¸ÓÁö Á¾¾ç¿¡´Â 15 Gy¸¦ ´ÜÀÏ Á¶»çÇÏ¿´´Ù. TNF-¥á
´Â ½ÇÇè½Ç ¸¶¿ì½º´ç ÇÏ·ç 10 ¥ìg¾¿ 7ÀÏ°£ ¿¬¼Ó ÁÖ»çÇÏ¿´´Ù. Ä¡·á °á°ú´Â Á¾¾ç¼ºÀåÁö¿¬ ºÐ¼®
¹ýÀ¸·Î Æò°¡ÇÏ¿´´Ù.
°á °ú : TNF-¥á ´Üµ¶ Åõ¿©½Ã ³×°¡Áö Á¾¾ç Áß MCa-K ¹× OCa-I Á¾¾ç¿¡¼­ absolute
growth delay (AGD)°¡ °¢°¢ 5.0ÀÏ, 6.5ÀÏ·Î À¯ÀÇÇÑ Ç×¾Ï È¿°ú°¡ ÀÖ¾ú´Ù. TNF-¥á¿Í ¹æ»ç¼±
À» º´¿ëÇÑ °æ¿ì OCa-I¿¡¼­´Â AGD°¡ TNF-¥á ´Üµ¶ÀÇ 6.5ÀÏ, ¹æ»ç¼±ÀÇ 26.9ÀÏ¿¡ ºñÇÏ¿©
TNF-¥á¿Í ¹æ»ç¼± º´¿ë½Ã 41.1ÀÏ·Î ÀÇÀÇÀÖ°Ô Áõ°¡ÇÏ¿´´Ù (p<0.05). EF´Â 1ÀÌ»óÀ¸·Î¼­ (EF:
1.29) TNF-¥á¿Í ¹æ»ç¼± º´¿ë½Ã Áõ°­È¿°ú°¡ ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. ³ª¸ÓÁö ¼¼ Á¾¾ç¿¡¼­´Â
TNF-¥á ´Üµ¶ ¹× ¹æ»ç¼± ´Üµ¶¿¡ ºñÇÏ¿© TNF-¥á¿Í ¹æ»ç¼± º´¿ë½Ã AGDÀÇ À¯ÀÇÇÑ Áõ°¡´Â
°üÂûµÇÁö ¾Ê¾Ò´Ù.
°á ·Ð : TNF-¥á´Â ¸¶¿ì½º µ¿Á¾¾Ï Áß ÀϺΠÁ¾¾ç (MCa-K ¹× OCa-I)¿¡¼­ Ç×¾Ï È¿°ú¸¦ º¸
¿´´Ù. ¹æ»ç¼±°ú º´¿ëÇÑ °æ¿ì¿¡µµ ÀϺΠÁ¾¾ç¿¡¼­¸¸ (OCa-I) ¹æ»ç¼±ÀÇ Ç×¾Ï È¿°ú¸¦ Áõ°­½ÃÅ°
´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. ÀÌ°°ÀÌ Á¾¾ç¿¡ µû¶ó ¹æ»ç¼±°ú TNF-¥áÀÇ º´¿ëÄ¡·á È¿°úÀÇ Á¤µµ°¡ ´Ù
¸£´Ù´Â Á¡Àº ÇâÈÄ ÀÓ»óÀû Àû¿ë¿¡ ´ëºñÇÑ À¯¿ëÇÑ ±âÃÊÀÚ·á·Î ¾²ÀÏ °ÍÀ¸·Î ±â´ëµÈ´Ù.

Purpose : To determine whether TNF-¥á increases the antitumor effect of
radiotherapy in murine syngeneic tumor system.
Materials and Methods : Syngeneic murine tumors of MCa-K or MCa-4(mammary
carcinoma), OCa-I (ovarian carcinoma). or HCa-I(hepatocarcinoma were grown in hind
legs of CBHf/HeJ mice. When tumors were grown to 6 mm in mean diameter, mice
were treated with TNF-¥á , radiation, or combination of the both. Gamma-radiation was
given as a single dose of 30 Gy for HCa-I and 15 Gy for other tumors using Cobalt-60
teletherapy unit. A novel TNF-¥á mutein developed in Korea, was intraperitoneally
administered daily at a dose of 10 ¥ìg Per mouse for 7 days. In combination of
radiation and TNF-¥á, the drug was started 1 hour after radiation. Tumor growth delay
assay was used to measure the tumor response to the treatment.
Results : Among 4 tested tumors, TNF-¥á alone showed significant antitumor activity
in MCa-K and OCa-I tumors, which showed absolute growth delay(AGD) of 5.0 days
and 6.5 days, respectively. In combination with radiation, TNF-¥á showed significant
delay of AGD (41.1 days) in OCA-I compared to AGDs of TNF-¥á alone and radiation,
i.e., 6.5 days and 26.9 days, respectively(P<0.05). Enhancement factor was 1.29 in OCa-I,
which showed supraadditive effect. TNF-¥á did not show significant delay of AGDs in
the remaining 3 tumors compared to AGDs of TNF-¥á alone and radiation.
Conclusions : TNF-¥á alone showed antitumor effects in MCa-K and OCa-I. In
combination with radiation, TNF-¥á acted in supraadditive way in OCa-I only. The
results of this study imply that the combination of TNF-¥á and radiation has different
therapeutic potential depending on tumor model and further study is advocated.

Å°¿öµå

TNF-¥á; Radiotherapy; Murine tumor;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS